Trial Profile
Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure (ULTIMATE-HF)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Udenafil (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms ULTIMATE-HF
- 31 Mar 2014 Primary endpoint 'Maximal-oxygen-consumption' has been met according to results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
- 31 Mar 2014 Results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
- 11 Apr 2013 Planned End Date changed from 1 Feb 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.